Calvin Lam
Lawyers
Filters
MiniMax Group HK$4.8 billion IPO
We advised MiniMax Group on its IPO and HKEX listing
HashKey Holdings HK$1.6 billion IPO
We advised HashKey on its IPO and HKEX listing
Pony AI HK$6.71 billion dual primary listing on the Hong Kong Stock Exchange
We advised Pony AI on its dual primary listing on HKEX
Seyond Holdings HK$11.7 billion de-SPAC transaction and private placement
We advised Seyond on the transactions
Anjoy Foods Group HK$2.4 billion public offering and HKEX listing
We advised Anjoy Foods on its public offering and listing of H shares
Guotai Junan merger with Haitong and concurrent placement of shares
We advised Guotai Junan Securities on the transaction, creating the largest securities company in China
MIXUE HK$3.45 billion IPO
We advised MIXUE on its IPO and HKEX listing
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Zhejiang Expressway $860 million rights issue
The H shares are listed on the Hong Kong Stock Exchange